Novo Nordisk faces $1.8 billion lawsuit over US insulin sale...

Novo Nordisk is facing a lawsuit from disgruntled investors seeking around $1.8 billion in compensation, saying the company failed to properly update the market about the situation regardin

Novo extends R&D alliance with AI specialist e-Therapeutics

Catalyst’s rival to NovoSeven hits the mark in phase 2 haemo...

Novo Nordisk’s Victoza gets FDA okay for paediatric use

Novo Nordisk’s GLP-1 agonist Victoza has become the first non-insulin drug to be approved in the US as a treatment for type 2 diabetes in children for almost two decades.

Novo Nordisk builds cardio claim case for oral semaglutide

Novo Nordisk’s bid to disrupt the diabetes market with an oral formulation of its GLP-1 agonist semaglutide has advanced again with new data showing it is safe for the heart.

Sanofi, Lilly and Novo make cases for diabetes drugs at ADA

The American Diabetes Association (ADA) annual conference has dominated the medical research headlines this weekend as pharma and biotech firms unveiled latest data from therapies for